Dendritic cell-based therapy in Type 1 diabetes mellitus

References

• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392, 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol.23, 445–449 (2002).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann. Rev. Immunol.21, 685–711 (2003).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med.191, 411–416 (2000).
   PubMed Web of Science ®Google Scholar
• Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J. Immunol.174, 5907–5914 (2005).
   PubMed Web of Science ®Google Scholar
• Apostolou I, Verginis P, Kretschmer K, Polansky J, Huhn J, von Boehmer H. Peripherally induced Treg: mode, stability, and role in specific tolerance. J. Clin. Immunol.28, 619–624 (2008).
   PubMed Web of Science ®Google Scholar
• Chappert P, Leboeuf M, Rameau P et al. Antigen-driven interactions with dendritic cells and expansion of Foxp3+ regulatory T cells occur in the absence of inflammatory signals. J. Immunol.180, 327–334 (2008).
   PubMed Web of Science ®Google Scholar
• Lonial S, Torre C, David E, Harris W, Arellano M, Waller EK. Regulation of alloimmune responses by dendritic cell subsets. Exp. Hematol.36, 1309–1317 (2008).
   PubMed Web of Science ®Google Scholar
• Marguti I, Yamamoto GL, da Costa TB, Rizzo LV, de Moraes LV. Expansion of CD4+ CD25+ Foxp3+ T cells by bone marrow-derived dendritic cells. Immunology127(1), 50–61 (2009).
   PubMed Web of Science ®Google Scholar
• Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol.7, 610–621 (2007).
   PubMed Web of Science ®Google Scholar
• Velasquez-Lopera MM, Correa LA, Garcia LF. Human spleen contains different subsets of dendritic cells and regulatory T lymphocytes. Clin. Exp. Immunol.154, 107–114 (2008).
   PubMedGoogle Scholar
• Smits HH, de Jong EC, Wierenga EA, Kapsenberg ML. Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol.26, 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Smits HH, Engering A, van der Kleij D et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Allergy Clin. Immunol.115, 1260–1267 (2005).
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Iyoda T, Tarbell K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med.198, 235–247 (2003).
   PubMed Web of Science ®Google Scholar
• Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med.172, 631–640 (1990).
   PubMed Web of Science ®Google Scholar
• Kubach J, Becker C, Schmitt E et al. Dendritic cells: sentinels of immunity and tolerance. Int. J. Hematol.81, 197–203 (2005).
   PubMed Web of Science ®Google Scholar
• Steinman RM. Some interfaces of dendritic cell biology. APMIS111, 675–697 (2003).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Bonifaz L, Fujii S et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol.560, 83–97 (2005).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl Acad. Sci. USA99, 351–358 (2002).
   PubMed Web of Science ®Google Scholar
• Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell106, 259–262 (2001).
   PubMed Web of Science ®Google Scholar
• Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol.2, 585–589 (2001).
   PubMed Web of Science ®Google Scholar
• Bluestone JA. Costimulation and its role in organ transplantation. Clin. Transplant.10, 104–109 (1996).
   PubMed Web of Science ®Google Scholar
• Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation80, 555–563 (2005).
   PubMed Web of Science ®Google Scholar
• Kishimoto K, Dong VM, Sayegh MH. The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Curr. Opin. Urol.10, 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann. Rev. Immunol.14, 233–258 (1996).
   PubMed Web of Science ®Google Scholar
• Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev.196, 85–108 (2003).
   PubMed Web of Science ®Google Scholar
• Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol.6, 1143–1150 (1995).
   PubMed Web of Science ®Google Scholar
• Manz MG, Traver D, Akashi K et al. Dendritic cell development from common myeloid progenitors. Ann. NY Acad. Sci.938, 167–173; discussion 173–174 (2001).
   PubMed Web of Science ®Google Scholar
• Manz MG, Traver D, Miyamoto T, Weissman IL, Akashi K. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood97, 3333–3341 (2001).
   PubMed Web of Science ®Google Scholar
• Manfredi AA, Sabbadini MG, Rovere-Querini P. Dendritic cells and the shadow line between autoimmunity and disease. Arthritis Rheum.52, 11–15 (2005).
   PubMed Web of Science ®Google Scholar
• Suciu-Foca N, Manavalan JS, Scotto L et al. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int. Immunopharmacol.5, 7–11 (2005).
   PubMed Web of Science ®Google Scholar
• Komulainen J, Knip M, Lounamaa R et al. Poor β-cell function after the clinical manifestation of Type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group. Diabet. Med.14, 532–537 (1997).
   PubMed Web of Science ®Google Scholar
• Lampeter EF, Klinghammer A, Scherbaum WA et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent Type 1 diabetes. DENIS Group. Diabetes47, 980–984 (1998).
   PubMed Web of Science ®Google Scholar
• Larsen MO, Rolin B, Gotfredsen CF, Carr RD, Holst JJ. Reduction of β cell mass: partial insulin secretory compensation from the residual β cell population in the nicotinamide-streptozotocin Gottingen minipig after oral glucose in vivo and in the perfused pancreas. Diabetologia47, 1873–1878 (2004).
   PubMed Web of Science ®Google Scholar
• Lohmann T, Kellner K, Verlohren HJ et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia44, 1005–1010 (2001).
   PubMed Web of Science ®Google Scholar
• Mayer A, Rharbaoui F, Thivolet C, Orgiazzi J, Madec AM. The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in Type 1 (insulin-dependent) diabetes mellitus. J. Clin. Endocrinol. Metab.84, 2419–2424 (1999).
   PubMed Web of Science ®Google Scholar
• Papoz L, Lenegre F, Hors J et al. Probability of remission in individual in early adult insulin dependent diabetic patients. Results from the Cyclosporine Diabetes French Study Group. Diabetes Metab.16, 303–310 (1990).
   PubMed Web of Science ®Google Scholar
• Petrone A, Galgani A, Spoletini M et al. Residual insulin secretion at diagnosis of Type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab. Res. Rev.21, 271–275 (2005).
   PubMed Web of Science ®Google Scholar
• Rasmussen SB, Sorensen TS, Hansen JB, Mandrup-Poulsen T, Hornum L, Markholst H. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual β-cell function and mass in acutely diabetic BB rats. Horm. Metab. Res.32, 294–300 (2000).
   PubMed Web of Science ®Google Scholar
• Shimada A, Imazu Y, Morinaga S et al. T-cell insulitis found in anti-GAD65+ diabetes with residual β-cell function. A case report. Diabetes Care22, 615–617 (1999).
   PubMed Web of Science ®Google Scholar
• Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes48, 989–996 (1999).
   PubMed Web of Science ®Google Scholar
• Weets I, Truyen I, Verschraegen I et al. Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated Type 1 diabetes. Diabetologia49, 1158–1162 (2006).
   PubMed Web of Science ®Google Scholar
• Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J. Immunol.160, 2684–2691 (1998).
   PubMed Web of Science ®Google Scholar
• Corbett JA, McDaniel ML. Reversibility of interleukin-1 β-induced islet destruction and dysfunction by the inhibition of nitric oxide synthase. Biochem. J.299(Pt 3), 719–724 (1994).
   PubMed Web of Science ®Google Scholar
• Corbett JA, Wang JL, Hughes JH et al. Nitric oxide and cyclic GMP formation induced by interleukin 1 β in islets of Langerhans. Evidence for an effector role of nitric oxide in islet dysfunction. Biochem. J.287(Pt 1), 229–235 (1992).
   PubMed Web of Science ®Google Scholar
• Corbett JA, Wang JL, Misko TP, Zhao W, Hickey WF, McDaniel ML. Nitric oxide mediates IL-1 β-induced islet dysfunction and destruction: prevention by dexamethasone. Autoimmunity15, 145–153 (1993).
   PubMed Web of Science ®Google Scholar
• Sai P, Rivereau AS, Granier C, Haertle T, Martignat L. Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524–543 reduces cyclophosphamide-accelerated diabetes. Clin. Exp. Immunol.105, 330–337 (1996).
   PubMed Web of Science ®Google Scholar
• McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med.211, 24–32 (1996).
   PubMed Web of Science ®Google Scholar
• Scarim AL, Heitmeier MR, Corbett JA. Irreversible inhibition of metabolic function and islet destruction after a 36-hour exposure to interleukin-1β. Endocrinology138, 5301–5307 (1997).
   PubMed Web of Science ®Google Scholar
• Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT. Neonatal β-cell apoptosis: a trigger for autoimmune diabetes? Diabetes49, 1–7 (2000).
   PubMed Web of Science ®Google Scholar
• Oldstone MB. Molecular mimicry and autoimmune disease. Cell50, 819–820 (1987).
   PubMed Web of Science ®Google Scholar
• Oldstone MB. Virus-induced autoimmunity: molecular mimicry as a route to autoimmune disease. J. Autoimmun.2(Suppl.), 187–194 (1989).
   PubMed Web of Science ®Google Scholar
• Oldstone MB. Molecular mimicry as a mechanism for the cause and a probe uncovering etiologic agent(s) of autoimmune disease. Curr. Top. Microbiol. Immunol.145, 127–135 (1989).
   PubMed Web of Science ®Google Scholar
• Conrad B, Weidmann E, Trucco G et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature371, 351–355 (1994).
   PubMed Web of Science ®Google Scholar
• Conrad B, Trucco M. Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. Diabetes Metab. Rev.10, 309–338 (1994).
   PubMed Web of Science ®Google Scholar
• Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and β-cell destruction in NOD mice. Diabetes43, 667–675 (1994).
   PubMed Web of Science ®Google Scholar
• Jansen A, Rosmalen JG, Homo-Delarche F, Dardenne M, Drexhage HA. Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on β-cell rest? J. Autoimmun.9, 341–348 (1996).
   PubMed Web of Science ®Google Scholar
• Lo D, Reilly CR, Scott B, Liblau R, McDevitt HO, Burkly LC. Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. Eur. J. Immunol.23, 1693–1698 (1993).
   PubMed Web of Science ®Google Scholar
• Clare-Salzler M, Mullen Y. Marked dendritic cell–T cell cluster formation in the pancreatic lymph node of the non-obese diabetic mouse. Immunology76, 478–484 (1992).
   PubMed Web of Science ®Google Scholar
• Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med.189, 331–339 (1999).
   PubMed Web of Science ®Google Scholar
• Shimizu J, Carrasco-Marin E, Kanagawa O, Unanue ER. Relationship between β cell injury and antigen presentation in NOD mice. J. Immunol.155, 4095–4099 (1995).
   PubMed Web of Science ®Google Scholar
• Green EA, Eynon EE, Flavell RA. Local expression of TNF-α in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity9, 733–743 (1998).
   PubMed Web of Science ®Google Scholar
• Dahlen E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-α in pancreatic islets in the nonobese diabetic mouse. J. Immunol.160, 3585–3593 (1998).
   PubMed Web of Science ®Google Scholar
• Ehl S, Hombach J, Aichele P et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J. Exp. Med.187, 763–774 (1998).
   PubMed Web of Science ®Google Scholar
• Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. Dendritic cells efficiently induce protective antiviral immunity. J. Virol.72, 3812–3818 (1998).
   PubMed Web of Science ®Google Scholar
• Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J. Exp. Med.188, 1493–1501 (1998).
   PubMed Web of Science ®Google Scholar
• Christen U, von Herrath MG. Transgenic animal models for Type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model. Transgenic. Res.11, 587–595 (2002).
   PubMed Web of Science ®Google Scholar
• Christen U, von Herrath MG. Manipulating the Type 1 vs Type 2 balance in Type 1 diabetes. Immunol. Res.30, 309–325 (2004).
   PubMed Web of Science ®Google Scholar
• Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol. Immunol.40, 1113–1120 (2004).
   PubMed Web of Science ®Google Scholar
• von Herrath MG. Regulation of virally induced autoimmunity and immunopathology: contribution of LCMV transgenic models to understanding autoimmune insulin-dependent diabetes mellitus. Curr. Top. Microbiol. Immunol.263, 145–175 (2002).
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol.13, 114–119 (2001).
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol.12, 991–1045 (1994).
   PubMed Web of Science ®Google Scholar
• Matzinger P. An innate sense of danger. Semin. Immunol.10, 399–415 (1998).
   PubMed Web of Science ®Google Scholar
• Matzinger P. Essay 1: the Danger Model in its historical context. Scand J. Immunol.54, 4–9 (2001).
   PubMed Web of Science ®Google Scholar
• Matzinger P. An innate sense of danger. Ann. NY Acad. Sci.961, 341–342 (2002).
   PubMed Web of Science ®Google Scholar
• Marleau AM, Singh B. Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J. Autoimmun.19, 23–35 (2002).
   PubMed Web of Science ®Google Scholar
• Sen P, Bhattacharyya S, Wallet M et al. NF-κB hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J. Immunol.170, 1770–1780 (2003).
   PubMed Web of Science ®Google Scholar
• Weaver DJ Jr, Poligone B, Bui T, Abdel-Motal UM, Baldwin AS Jr, Tisch R. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive IkB kinase. J. Immunol.167, 1461–1468 (2001).
   PubMed Web of Science ®Google Scholar
• Wheat W, Kupfer R, Gutches DG et al. Increased NF-κB activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur. J. Immunol.34, 1395–1404 (2004).
   PubMed Web of Science ®Google Scholar
• Boudaly S, Morin J, Berthier R, Marche P, Boitard C. Altered dendritic cells (DC) might be responsible for regulatory T cell imbalance and autoimmunity in nonobese diabetic (NOD) mice. Eur. Cytokine Netw.13, 29–37 (2002).
   PubMed Web of Science ®Google Scholar
• Nikolic T, Bunk M, Drexhage HA, Leenen PJ. Bone marrow precursors of nonobese diabetic mice develop into defective macrophage-like dendritic cells in vitro. J. Immunol.173, 4342–4351 (2004).
   PubMed Web of Science ®Google Scholar
• Strid J, Lopes L, Marcinkiewicz J et al. A defect in bone marrow derived dendritic cell maturation in the nonobese diabetic mouse. Clin. Exp. Immunol.123, 375–381 (2001).
   PubMed Web of Science ®Google Scholar
• Eibl N, Spatz M, Fischer GF et al. Impaired primary immune response in Type-1 diabetes: results from a controlled vaccination study. Clin. Immunol.103, 249–259 (2002).
   PubMed Web of Science ®Google Scholar
• McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect. Dis. Clin. North Am.9, 1–9 (1995).
   PubMed Web of Science ®Google Scholar
• Wheat LJ. Infection and diabetes mellitus. Diabetes Care3, 187–197 (1980).
   PubMed Web of Science ®Google Scholar
• Peng R, Li Y, Brezner K, Litherland S, Clare-Salzler MJ. Abnormal peripheral blood dendritic cell populations in Type 1 diabetes. Ann. NY Acad. Sci.1005, 222–225 (2003).
   PubMed Web of Science ®Google Scholar
• Summers KL, Behme MT, Mahon JL, Singh B. Characterization of dendritic cells in humans with Type 1 diabetes. Ann. NY Acad. Sci.1005, 226–229 (2003).
   PubMed Web of Science ®Google Scholar
• Summers KL, Marleau AM, Mahon JL, McManus R, Hramiak I, Singh B. Reduced IFN-α secretion by blood dendritic cells in human diabetes. Clin. Immunol.121, 81–89 (2006).
   PubMed Web of Science ®Google Scholar
• Coates PT, Thomson AW. Dendritic cells, tolerance induction and transplant outcome. Am. J. Transplant.2, 299–307 (2002).
   PubMed Web of Science ®Google Scholar
• Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J. Leukoc. Biol.73, 3–29 (2003).
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Anichini A, Mortarini R, Bregni M, Parmiani G, Gianni AM. Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cytokines Cell Mol. Ther.4, 265–273 (1998).
   PubMedGoogle Scholar
• Hackstein H, Morelli AE, Thomson AW. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol.22, 437–442 (2001).
   PubMed Web of Science ®Google Scholar
• Hardin JA. Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann. Rheum. Dis.64(Suppl 4), iv86–iv90 (2005).
   PubMed Web of Science ®Google Scholar
• Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev.196, 125–146 (2003).
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Thomson AW. Dendritic cells as promoters of transplant tolerance. Expert Opin. Biol. Ther.6, 325–339 (2006).
   PubMed Web of Science ®Google Scholar
• Paul S, Calmels B, Acres RB. Improvement of adoptive cellular immunotherapy of human cancer using ex vivo gene transfer. Curr. Gene Ther.2, 91–100 (2002).
   PubMedGoogle Scholar
• Steinman RM, Inaba K, Turley S, Pierre P, Mellman I. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum. Immunol.60, 562–567 (1999).
   PubMed Web of Science ®Google Scholar
• Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes48, 2300–2308 (1999).
   PubMed Web of Science ®Google Scholar
• Bottino R, Lemarchand P, Trucco M, Giannoukakis N. Gene- and cell-based therapeutics for Type I diabetes mellitus. Gene Ther.10, 875–889 (2003).
   PubMed Web of Science ®Google Scholar
• Chen D, Sung R, Bromberg JS. Gene therapy in transplantation. Transpl. Immunol.9, 301–314 (2002).
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Rudert WA, Robbins PD, Trucco M. Targeting autoimmune diabetes with gene therapy. Diabetes48, 2107–2121 (1999).
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Thomson A, Robbins P. Gene therapy in transplantation. Gene Ther.6, 1499–1511 (1999).
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Trucco M. Gene therapy for Type 1 diabetes. Am. J. Ther.12, 512–528 (2005).
   PubMed Web of Science ®Google Scholar
• Tarner IH, Fathman CG. The potential for gene therapy in the treatment of autoimmune disease. Clin. Immunol.104, 204–216 (2002).
   PubMed Web of Science ®Google Scholar
• Tarner IH, Slavin AJ, McBride J et al. Treatment of autoimmune disease by adoptive cellular gene therapy. Ann. NY Acad. Sci.998, 512–519 (2003).
   PubMed Web of Science ®Google Scholar
• Trucco M, Robbins PD, Thomson AW, Giannoukakis N. Gene therapy strategies to prevent autoimmune disorders. Curr. Gene Ther.2, 341–354 (2002).
   PubMedGoogle Scholar
• Chen W. Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front. Biosci.11, 1360–1370 (2006).
   PubMed Web of Science ®Google Scholar
• Hugues S, Boissonnas A, Amigorena S, Fetler L. The dynamics of dendritic cell–T cell interactions in priming and tolerance. Curr. Opin. Immunol.18, 491–495 (2006).
   PubMed Web of Science ®Google Scholar
• Beissert S, Schwarz A, Schwarz T. Regulatory T cells. J. Invest. Dermatol.126, 15–24 (2006).
   PubMed Web of Science ®Google Scholar
• Enk AH. DCs and cytokines cooperate for the induction of Tregs. Ernst Schering Res. Found. Workshop56, 97–106 (2006).
   PubMedGoogle Scholar
• Huber S, Schramm C. TGF-β and CD4+CD25+ regulatory T cells. Front. Biosci.11, 1014–1023 (2006).
   PubMed Web of Science ®Google Scholar
• Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol. Rev.212, 149–162 (2006).
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev.212, 28–50 (2006).
   PubMed Web of Science ®Google Scholar
• Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev.212, 60–73 (2006).
   PubMed Web of Science ®Google Scholar
• Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev.212, 217–237 (2006).
   PubMed Web of Science ®Google Scholar
• Verhagen J, Blaser K, Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. Immunol. Allergy Clin. North Am.26, 207–231, vi (2006).
   PubMed Web of Science ®Google Scholar
• Zhang L, Yi H, Xia XP, Zhao Y. Transforming growth factor-β: an important role in CD4+CD25+ regulatory T cells and immune tolerance. Autoimmunity39, 269–276 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson CC, Chan WF. Mechanisms and models of peripheral CD4 T cell self-tolerance. Front. Biosci.9, 2947–2963 (2004).
   PubMed Web of Science ®Google Scholar
• Balomenos D, Martinez AC. Cell-cycle regulation in immunity, tolerance and autoimmunity. Immunol. Today21, 551–555 (2000).
   PubMedGoogle Scholar
• Brennan PJ, Saouaf SJ, Greene MI, Shen Y. Anergy and suppression as coexistent mechanisms for the maintenance of peripheral T cell tolerance. Immunol. Res.27, 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature435, 590–597 (2005).
   PubMed Web of Science ®Google Scholar
• Lechler R, Chai JG, Marelli-Berg F, Lombardi G. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology103, 262–269 (2001).
   PubMed Web of Science ®Google Scholar
• Lechler R, Chai JG, Marelli-Berg F, Lombardi G. T-cell anergy and peripheral T-cell tolerance. Philos. Trans. R. Soc. Lond. B Biol. Sci.356, 625–637 (2001).
   PubMed Web of Science ®Google Scholar
• Saouaf SJ, Brennan PJ, Shen Y, Greene MI. Mechanisms of peripheral immune tolerance: conversion of the immune to the unresponsive phenotype. Immunol. Res.28, 193–199 (2003).
   PubMed Web of Science ®Google Scholar
• Singh NJ, Schwartz RH. Primer: mechanisms of immunologic tolerance. Nat. Clin. Pract. Rheumatol.2, 44–52 (2006).
   PubMedGoogle Scholar
• Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to their clinical application. Semin. Immunol.18, 120–127 (2006).
   PubMed Web of Science ®Google Scholar
• Mennechet FJ, Uze G. Interferon-γ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood107, 4417–4423 (2006).
   PubMed Web of Science ®Google Scholar
• Rutella S, Bonanno G, Procoli A et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood108, 218–227 (2006).
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood104, 26–33 (2004).
   PubMed Web of Science ®Google Scholar
• Watanabe N, Wang YH, Lee HK et al. Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature436, 1181–1185 (2005).
   PubMed Web of Science ®Google Scholar
• Yvon ES, Vigouroux S, Rousseau RF et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood102, 3815–3821 (2003).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med.193, 233–238 (2001).
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med.192, 1213–1222 (2000).
   PubMed Web of Science ®Google Scholar
• Brinster C, Shevach EM. Bone marrow-derived dendritic cells reverse the anergic state of CD4+CD25+ T cells without reversing their suppressive function. J. Immunol.175, 7332–7340 (2005).
   PubMed Web of Science ®Google Scholar
• Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med.199, 1467–1477 (2004).
   PubMed Web of Science ®Google Scholar
• DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. Autoantigen-specific TGFβ-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol.179, 4685–4693 (2007).
   PubMed Web of Science ®Google Scholar
• Lehner T. Special regulatory T cell review: the resurgence of the concept of contrasuppression in immunoregulation. Immunology123, 40–44 (2008).
   PubMed Web of Science ®Google Scholar
• Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA105, 10113–10118 (2008).
   PubMed Web of Science ®Google Scholar
• Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am. J. Transplant8, 298–306 (2008).
   PubMedGoogle Scholar
• Harnaha J, Machen J, Wright M et al. Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes55, 158–170 (2006).
   PubMed Web of Science ®Google Scholar
• Ma L, Qian S, Liang X et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-κB activity. Diabetes52, 1976–1985 (2003).
   PubMed Web of Science ®Google Scholar
• Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol.173, 4331–4341 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips B, Nylander K, Harnaha J et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes57, 1544–1555 (2008).
   PubMed Web of Science ®Google Scholar
• Gordon EJ, Wicker LS, Peterson LB et al. Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. Diabetes54, 107–115 (2005).
   PubMed Web of Science ®Google Scholar
• Markees TG, Serreze DV, Phillips NE et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes48, 967–974 (1999).
   PubMed Web of Science ®Google Scholar
• Pearson T, Markees TG, Serreze DV et al. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J. Immunol.171, 185–195 (2003).
   PubMed Web of Science ®Google Scholar
• Pearson T, Markees TG, Serreze DV et al. Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? Ann. NY Acad. Sci.1005, 148–156 (2003).
   PubMed Web of Science ®Google Scholar
• Pearson T, Markees TG, Wicker LS et al. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes52, 321–326 (2003).
   PubMed Web of Science ®Google Scholar
• Rossini AA. Autoimmune diabetes and the circle of tolerance. Diabetes53, 267–275 (2004).
   PubMed Web of Science ®Google Scholar
• Rossini AA, Mordes JP, Greiner DL, Stoff JS. Islet cell transplantation tolerance. Transplantation72, S43–S46 (2001).
   PubMed Web of Science ®Google Scholar
• Seung E, Mordes JP, Greiner DL, Rossini AA. Induction of tolerance for islet transplantation for Type 1 diabetes. Curr. Diab. Rep.3, 329–335 (2003).
   PubMedGoogle Scholar
• Banchereau J, Fay J, Pascual V, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found. Symp.252, 226–235 (2003).
   PubMedGoogle Scholar
• Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev.19, 41–52 (2008).
   PubMed Web of Science ®Google Scholar
• Hsu W, Shu SA, Gershwin E, Lian ZX. The current immune function of hepatic dendritic cells. Cell Mol. Immunol.4, 321–328 (2007).
   PubMed Web of Science ®Google Scholar
• Kuwana M. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum. Immunol.63, 1156–1163 (2002).
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Wright TM, Kawakami Y, Ikeda Y. Induction of antigen-specific human CD4+ T cell anergy by peripheral blood DC2 precursors. Eur. J. Immunol.31, 2547–2557 (2001).
   PubMed Web of Science ®Google Scholar
• Lian ZX, Okada T, He XS et al. Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J. Immunol.170, 2323–2330 (2003).
   PubMed Web of Science ®Google Scholar
• Liang X, Ma L, Thai NL, Fung JJ, Qian S, Lu L. The role of liver-derived regulatory dendritic cells in prevention of Type 1 diabetes. Immunology120, 251–260 (2007).
   PubMed Web of Science ®Google Scholar
• Monrad S, Kaplan MJ. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol. Res.37, 135–145 (2007).
   PubMed Web of Science ®Google Scholar
• Vuckovic S, Withers G, Harris M et al. Decreased blood dendritic cell counts in Type 1 diabetic children. Clin. Immunol.123, 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity18, 605–617 (2003).
   PubMed Web of Science ®Google Scholar
• Young JW, Merad M, Hart DN. Dendritic cells in transplantation and immune-based therapies. Biol. Blood Marrow Transplant.13, 23–32 (2007).
   PubMed Web of Science ®Google Scholar
• Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl. Immunol.11, 345–356 (2003).
   PubMed Web of Science ®Google Scholar
• Gilliet M, Liu YJ. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum. Immunol.63, 1149–1155 (2002).
   PubMed Web of Science ®Google Scholar
• Hochrein H, O’Keeffe M, Wagner H. Human and mouse plasmacytoid dendritic cells. Hum. Immunol.63, 1103–1110 (2002).
   PubMed Web of Science ®Google Scholar
• Ito T, Liu YJ, Kadowaki N. Functional diversity and plasticity of human dendritic cell subsets. Int. J. Hematol.81, 188–196 (2005).
   PubMed Web of Science ®Google Scholar
• Magyarics Z, Rajnavolgyi E. Professional type I interferon-producing cells: a unique subpopulation of dendritic cells. Acta Microbiol. Immunol. Hung.52, 443–462 (2005).
   PubMedGoogle Scholar
• Palucka AK, Banchereau J, Blanco P, Pascual V. The interplay of dendritic cell subsets in systemic lupus erythematosus. Immunol. Cell Biol.80, 484–488 (2002).
   PubMed Web of Science ®Google Scholar
• Rossi M, Arpinati M, Rondelli D, Anasetti C. Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation? Hum. Immunol.63, 1194–1200 (2002).
   PubMed Web of Science ®Google Scholar
• Soumelis V, Liu YJ. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur. J. Immunol.36, 2286–2292 (2006).
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Furue M. Dendritic cells: ontogeny. Allergol. Int.56, 215–223 (2007).
   PubMedGoogle Scholar
• Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity29, 352–361 (2008).
   PubMed Web of Science ®Google Scholar
• Xiao BG, Huang YM, Link H. Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases. BioDrugs17, 103–111 (2003).
   PubMed Web of Science ®Google Scholar
• Bergeron A, El-Hage F, Kambouchner M, Lecossier D, Tazi A. Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur. Respir. J.28, 1170–1177 (2006).
   PubMed Web of Science ®Google Scholar
• Briard D, Azzarone B, Brouty-Boye D. Importance of stromal determinants in the generation of dendritic and natural killer cells in the human spleen. Clin. Exp. Immunol.140, 265–273 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng P, Nefedova Y, Corzo CA, Gabrilovich DI. Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood109, 507–515 (2007).
   PubMed Web of Science ®Google Scholar
• Despars G, Ni K, Bouchard A, O’Neill TJ, O’Neill HC. Molecular definition of an in vitro niche for dendritic cell development. Exp. Hematol.32, 1182–1193 (2004).
   PubMed Web of Science ®Google Scholar
• Despars G, Periasamy P, Tan J, Abbey J, O’Neill TJ, O’Neill HC. Gene signature of stromal cells which support dendritic cell development. Stem Cells Dev.17, 917–927 (2008).
   PubMed Web of Science ®Google Scholar
• Despars G, Tan J, Periasamy P, O’Neill HC. The role of stroma in hematopoiesis and dendritic cell development. Curr. Stem Cell Res. Ther.2, 23–29 (2007).
   PubMedGoogle Scholar
• Feuerer M, Beckhove P, Mahnke Y et al. Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. Int. J. Oncol.25, 867–876 (2004).
   PubMed Web of Science ®Google Scholar
• Glanville SH, Bekiaris V, Jenkinson EJ, Lane PJ, Anderson G, Withers DR. Transplantation of embryonic spleen tissue reveals a role for adult non-lymphoid cells in initiating lymphoid tissue organization. Eur. J. Immunol.39, 280–289 (2008).
   Web of Science ®Google Scholar
• Li Q, Guo Z, Xu X, Xia S, Cao X. Pulmonary stromal cells induce the generation of regulatory DC attenuating T-cell-mediated lung inflammation. Eur. J. Immunol.38, 2751–2761 (2008).
   PubMed Web of Science ®Google Scholar
• O’Neill HC, Jonas N, Wilson H, Ni K. Immunotherapeutic potential of dendritic cells generated in long-term stroma-dependent cultures. Cancer Biother. Radiopharm.14, 263–276 (1999).
   PubMed Web of Science ®Google Scholar
• Tan JK, O’Neill HC. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J. Leukoc. Biol.78, 319–324 (2005).
   PubMed Web of Science ®Google Scholar
• Xia S, Guo Z, Xu X, Yi H, Wang Q, Cao X. Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance. Blood112, 3175–3185 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang M, Tang H, Guo Z et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol.5, 1124–1133 (2004).
   PubMed Web of Science ®Google Scholar
• Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr. Pharm. Des.12, 807–817 (2006).
   PubMed Web of Science ®Google Scholar
• Kikuchi T. Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med.208, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Pinzon-Charry A, Schmidt C, Lopez JA. Dendritic cell immunotherapy for breast cancer. Expert Opin. Biol. Ther.6, 591–604 (2006).
   PubMed Web of Science ®Google Scholar
• Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front. Biosci.11, 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Saito H, Frleta D, Dubsky P, Palucka AK. Dendritic cell-based vaccination against cancer. Hematol. Oncol. Clin. North Am.20, 689–710 (2006).
   PubMed Web of Science ®Google Scholar
• Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res.16, 241–259 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four a-fetoprotein peptides. Clin. Cancer Res.12, 2817–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Dillman R, Selvan S, Schiltz P et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF. planned interim analysis. Cancer Biother. Radiopharm.19, 658–665 (2004).
   PubMed Web of Science ®Google Scholar
• Hersey P, Menzies SW, Halliday GM et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother.53, 125–134 (2004).
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther.13, 905–918 (2006).
   PubMed Web of Science ®Google Scholar
• Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a Phase II clinical trial. Cancer Res.60, 829–833 (2000).
   PubMed Web of Science ®Google Scholar
• Lou E, Marshall J, Aklilu M, Cole D, Chang D, Morse M. A Phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin. Colorectal Cancer5, 368–371 (2006).
   PubMed Web of Science ®Google Scholar
• Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother.51, 637–644 (2002).
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Boczkowski D et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int. J. Gastrointest. Cancer32, 1–6 (2002).
   PubMedGoogle Scholar
• O’Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother.52, 387–395 (2003).
   PubMed Web of Science ®Google Scholar
• Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother.51, 669–673 (2002).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol.21, 4016–4026 (2003).
   PubMed Web of Science ®Google Scholar
• Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate36, 39–44 (1998).
   PubMed Web of Science ®Google Scholar
• Tjoa BA, Simmons SJ, Elgamal A et al. Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate40, 125–129 (1999).
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Ansen S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res.11, 5993–6001 (2005).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer89, 1172–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res.11, 4160–4167 (2005).
   PubMed Web of Science ®Google Scholar
• O’Doherty U, Peng M, Gezelter S et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology82, 487–493 (1994).
   PubMed Web of Science ®Google Scholar
• Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med.185, 1101–1111 (1997).
   PubMed Web of Science ®Google Scholar
• Clare-Salzler MJ, Brooks J, Chai A, van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest.90, 741–748 (1992).
   PubMed Web of Science ®Google Scholar
• Creusot RJ, Yaghoubi SS, Kodama K et al. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin. Immunol.127, 176–187 (2008).
   PubMed Web of Science ®Google Scholar
• Feili-Hariri M, Falkner DH, Gambotto A et al. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum. Gene Ther.14, 13–23 (2003).
   PubMed Web of Science ®Google Scholar
• Luo X, Tarbell KV, Yang H et al. Dendritic cells with TGF-β1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA104, 2821–2826 (2007).
   PubMed Web of Science ®Google Scholar
• Hernandez A, Burger M, Blomberg BB et al. Inhibition of NF-κB during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches. Hum. Immunol.68, 715–729 (2007).
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb. Exp. Pharmacol.251–273 (2009).
   PubMedGoogle Scholar
• Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. NY Acad. Sci.987, 258–261 (2003).
   PubMed Web of Science ®Google Scholar
• Besin G, Gaudreau S, Menard M, Guindi C, Dupuis G, Amrani A. Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes57, 2107–2117 (2008).
   PubMed Web of Science ®Google Scholar
• Buckland M, Lombardi G. Aspirin and the induction of tolerance by dendritic cells. Handb. Exp. Pharmacol.188, 197–213 (2009).
   PubMedGoogle Scholar
• Kared H, Masson A, Adle-Biassette H, Bach JF, Chatenoud L, Zavala F. Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4+CD25+ regulatory T-cells. Diabetes54, 78–84 (2005).
   PubMed Web of Science ®Google Scholar
• Morin J, Faideau B, Gagnerault MC, Lepault F, Boitard C, Boudaly S. Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice. Handb. Exp. Pharmacol.134, 388–395 (2003).
   Google Scholar
• Papaccio G, Nicoletti F, Pisanti FA, Bendtzen K, Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology141, 1500–1505 (2000).
   PubMed Web of Science ®Google Scholar
• Steptoe RJ, Ritchie JM, Jones LK, Harrison LC. Autoimmune diabetes is suppressed by transfer of proinsulin-encoding Gr-1+ myeloid progenitor cells that differentiate in vivo into resting dendritic cells. Diabetes54, 434–442 (2005).
   PubMed Web of Science ®Google Scholar
• Menges M, Rossner S, Voigtlander C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor a induce antigen-specific protection of mice from autoimmunity. J. Exp. Med.195, 15–21 (2002).
   PubMed Web of Science ®Google Scholar
• Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J. Immunol.174, 7433–7439 (2005).
   PubMed Web of Science ®Google Scholar
• Gangi E, Vasu C, Cheatem D, Prabhakar BS. IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol.174, 7006–7013 (2005).
   PubMed Web of Science ®Google Scholar
• Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood107, 3787–3794 (2006).
   PubMed Web of Science ®Google Scholar
• Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl Acad. Sci. USA102, 13562–13567 (2005).
   PubMed Web of Science ®Google Scholar
• Faunce DE, Terajewicz A, Stein-Streilein J. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J. Immunol.172, 1991–1995 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang H, Xiao B et al. Dendritic cells transduced with lentiviral-mediated RelB-specific ShRNAs inhibit the development of experimental autoimmune myasthenia gravis. Mol. Immunol.46(4), 657–667 (2008).
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol.166, 3499–3505 (2001).
   PubMed Web of Science ®Google Scholar
• Kim SH, Lechman ER, Bianco N et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol.174, 6440–6448 (2005).
   PubMed Web of Science ®Google Scholar
• Whalen JD, Thomson AW, Lu L, Robbins PD, Evans CH. Viral IL-10 gene transfer inhibits DTH responses to soluble antigens: evidence for involvement of genetically modified dendritic cells and macrophages. Mol. Ther.4, 543–550 (2001).
   PubMed Web of Science ®Google Scholar
• Hoves S, Krause SW, Halbritter D et al. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J. Immunol.170, 5406–5413 (2003).
   PubMed Web of Science ®Google Scholar
• Hoves S, Krause SW, Herfarth H et al. Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing killer-dendritic cells. Immunobiology208, 463–475 (2004).
   PubMed Web of Science ®Google Scholar
• Torisu M, Murakami H, Akbar F et al. Protective role of interleukin-10-producing regulatory dendritic cells against murine autoimmune gastritis. J. Gastroenterol.43, 100–107 (2008).
   PubMed Web of Science ®Google Scholar
• Henry E, Desmet CJ, Garze V et al. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J. Immunol.181, 7230–7242 (2008).
   PubMed Web of Science ®Google Scholar
• Wu K, Bi Y, Sun K, Xia J, Wang Y, Wang C. Suppression of allergic inflammation by allergen-DNA-modified dendritic cells depends on the induction of Foxp3+ regulatory T cells. Scand. J. Immunol.67, 140–151 (2008).
   PubMed Web of Science ®Google Scholar
• Fu F, Li Y, Qian S et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation62, 659–665 (1996).
   PubMed Web of Science ®Google Scholar
• Lutz MB, Suri RM, Niimi M et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur. J. Immunol.30, 1813–1822 (2000).
   PubMed Web of Science ®Google Scholar
• Rastellini C, Lu L, Ricordi C, Starzl TE, Rao AS, Thomson AW. Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation60, 1366–1370 (1995).
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity18, 367–379 (2003).
   PubMed Web of Science ®Google Scholar
• Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol.167, 1945–1953 (2001).
   PubMed Web of Science ®Google Scholar
• Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA98, 6800–6805 (2001).
   PubMed Web of Science ®Google Scholar
• Hackstein H, Morelli AE, Larregina AT et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol.166, 7053–7062 (2001).
   PubMed Web of Science ®Google Scholar
• Hackstein H, Taner T, Zahorchak AF et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood101, 4457–4463 (2003).
   PubMed Web of Science ®Google Scholar
• Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol.4, 24–34 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kB. Transplantation68, 1255–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Ma L, Rudert WA, Harnaha J et al. Immunosuppressive effects of glucosamine. J. Biol. Chem.277, 39343–39349 (2002).
   PubMed Web of Science ®Google Scholar
• Matasic R, Dietz AB, Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology101, 53–60 (2000).
   PubMed Web of Science ®Google Scholar
• Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol.30, 1233–1242 (2000).
   PubMed Web of Science ®Google Scholar
• Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J. Immunol.165, 2374–2381 (2000).
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Guinet E. Direct and indirect cross-tolerance of alloreactive T cells by dendritic cells retained in the immature stage. Transplantation74, 1035–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Penna G, Adorini L. 1 A,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol.164, 2405–2411 (2000).
   PubMed Web of Science ®Google Scholar
• Piemonti L, Monti P, Allavena P et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol.162, 6473–6481 (1999).
   PubMed Web of Science ®Google Scholar
• Roelen DL, Schuurhuis DH, van den Boogaardt DE et al. Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation76, 1608–1615 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas JM, Contreras JL, Jiang XL et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation68, 1660–1673 (1999).
   PubMed Web of Science ®Google Scholar
• Vosters O, Neve J, De Wit D, Willems F, Goldman M, Verhasselt V. Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory T cells. Transplantation75, 383–389 (2003).
   PubMed Web of Science ®Google Scholar
• Bonham CA, Peng L, Liang X et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-κ B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J. Immunol.169, 3382–3391 (2002).
   PubMed Web of Science ®Google Scholar
• Coates PT, Krishnan R, Kireta S, Johnston J, Russ GR. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-SCID chimeric mice. Gene Ther.8, 1224–1233 (2001).
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Bransom J, Cattral M et al. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFβ and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. Clin. Immunol.95, 182–189 (2000).
   PubMed Web of Science ®Google Scholar
• Lu L, Gambotto A, Lee WC, Qian S, Bonham CA, Robbins PD, Thomson AW. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther.6, 554–563 (1999).
   PubMed Web of Science ®Google Scholar
• Min WP, Gorczynski R, Huang XY et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol.164, 161–167 (2000).
   PubMed Web of Science ®Google Scholar
• O’Rourke RW, Kang SM, Lower JA et al. A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival. Transplantation69, 1440–1446 (2000).
   PubMed Web of Science ®Google Scholar
• Takayama T, Morelli AE, Robbins PD, Tahara H, Thomson AW. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther.7, 1265–1273 (2000).
   PubMed Web of Science ®Google Scholar
• Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation66, 1567–1574 (1998).
   PubMed Web of Science ®Google Scholar
• Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med.196, 447–457 (2002).
   PubMed Web of Science ®Google Scholar
• Garrovillo M, Ali A, Oluwole SF. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells. Transplantation68, 1827–1834 (1999).
   PubMed Web of Science ®Google Scholar
• Kuo YR, Huang CW, Goto S et al. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation. J. Surg. Res. (2008).
   Google Scholar
• Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am. J. Transplant5, 228–236 (2005).
   PubMed Web of Science ®Google Scholar